A triphasic ceramic-coated porous hydroxyapatite for tissue engineering application

Nair, Manitha B.; Babu, S. Suresh; Varma, H. K.; John, Annie

doi:10.1016/j.actbio.2007.07.004

Cited by 71 publications

(48 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Due to the proven potential to facilitate bone healing, numerous ceramic scaffolds, granules and cements have been licensed and used for clinical indications and tissue engineering approaches (Hing, 2005;Habraken et al, 2007;Nair et al, 2007) but until today, we have to use them in vivo without knowing the accuracy of our diagnostic evaluation.…”

Section: Discussionmentioning

confidence: 99%

Comparison of computed tomography and microradiography for graft evaluation after reconstruction of critical size bone defects using β-tricalcium phosphate

Nolff

Kokemueller

Hauschild

et al. 2010

Journal of Cranio-Maxillofacial Surgery

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Comparison of computed tomography and microradiography for graft evaluation after reconstruction of critical size bone defects using β-tricalcium phosphate

Nolff

Kokemueller

Hauschild

et al. 2010

Journal of Cranio-Maxillofacial Surgery

View full text Add to dashboard Cite

“…HAp may serve not only as a bone filler but also as a carrier of active substances: antibiotics, chemiotherapeutics, growth factors, etc. [4][5][6][7][8][9]; it can also be used in composites, as a factor increasing their cytocompatibility, bioactivity, osteoconductivity, adhesion of coatings and compression modulus [10][11][12][13][14]. On the other hand, HAp application is often limited due to its relatively poor resorption and slow replacement by the host bone after implantation, substantially high Young modulus, and low fracture toughness [15,16], although these properties may be improved by addition of elasticity-increasing polymers.…”

Section: Introductionmentioning

confidence: 99%

Application of β-1,3-glucan in production of ceramics-based elastic composite for bone repair

et al. 2013

View full text Add to dashboard Cite

Application of β-1,3-glucan in production of ceramics-based elastic composite for bone repair IntroductionHydroxyapatite (HAp), especially in a porous form, is appreciated as a bone filler due to its biocompatibility, bioactivity, osteoconductivity, minimal risk of appearance of allergic reactions, lack of carcinogenic properties and lack of sensitivity to sterilization processes [1][2][3]. There are numerous commercially available bone graft materials based on biologic and synthetic HAp, including ProOsteon ® (Interpore Cross International, USA), Endobon (BIOMET Orthopaedics, Switzerland), Cerapatite (Ceraver Osteal, France), Synatite (SBM, France) and others. HAp may serve not only as a bone filler but also as a carrier of active substances: antibiotics, chemiotherapeutics, growth factors, etc. [4][5][6][7][8][9]; it can also be used in composites, as a factor increasing their cytocompatibility, bioactivity, osteoconductivity, adhesion of coatings and compression modulus [10][11][12][13][14]. On the other hand, HAp application is often limited due to its relatively poor resorption and slow replacement by the host bone after implantation, substantially high Young modulus, and low fracture toughness [15,16], although these properties may be improved by addition of elasticity-increasing polymers. It is considered that polymer-ceramic composites reveal superior properties (at least in some aspects) over polymer and ceramic alone [17]. However, most polymers used for bone filler fabrication meet only some of the criteria for implantable materials.Bone replacing material such as ceramics or crushed bone offers an insufficient surgical handiness, especially when the orthopedic surgeon has to handle granules (in case of defects in maxillary bone) or scaffolds (rigid and non-adaptable to the implantation site). Some commercially available biomaterials contain the artificial or natural polymers serving as plasticizing agents and thus significantly reduce this inconvenience. Among them, EasyGraft TM (Degradable Solutions SA, Switzerland), Plexur M and P (Osteotech, USA) and Cerapatite-Collagen (Ceraver Osteal, France) can be listed. EasyGraft TM contains PLGA-coated β-TCP granules which hardens into a compact mass via partial and temporary PLGA dissolution by organic solvent; Plexur M and P are composed of cortical bone and resorbable artificial polymer; Cerapatite-Collagen, made from HAp granules and naturally-derived collagen fibers, becomes elastic after hydration with blood or saline. Bone or ceramic granules and powders may also be turned into a paste using collagen gels (e.g., Tecnoss ® Gel O; Tecnoss, Italy) or fibrin glue [18,19]. However, the natural polymeric compounds used in commercially available composites (collagen, fibrin glue) originate from animal sources; this can be considered as a limiting factor because of the increased risk of transmissible contamination (e.g. viruses) and undesirable immune responses. Thus, the necessity of careful purification of these animal polymers exacts the high price of fin...

show abstract

“…Os resultados na literatura dependem das diversas formulações e ainda são inconclusivos quanto à quantidade e à qualidade do osso neoformado (6)(7)(8)(10)(11)(12)(13)(14) . Alterando-se sua composição (como a adição de ß-TCP) e seu método de fabricação, poderia ser modificada a velocidade de reabsorção da HA, que naturalmente ocorreria de forma muito lenta (8,9) .…”

Section: Discussionunclassified

Estudo comparativo da neoformação óssea utilizando-se o enxerto autógeno e três substitutos: defeitos ósseos em ratos

Stein¹,

Silva²,

Silva³

2009

Rev. bras. ortop.

View full text Add to dashboard Cite

RESUMOObjetivo: Comparar a percentagem de neoformação óssea promovida pelo enxerto ósseo autógeno e três tipos de materiais de substituição de características distintas em cavidades em fêmures de ratos. Métodos: Foram realizadas duas cavidades de 5,4 x 2,7mm, em cada fêmur (direito e esquerdo), de 14 ratos Wistar isogênicos. Cada um dos quatro defeitos criados foi preenchido com o osso autógeno ou com um dos três materiais testados -hidroxiapatita (HA), Genphos ® (HA+ ß-TCP) e GenMix ® (um enxerto ósseo bovino composto). Ao final dos períodos de seis semanas (n = 6) e 12 semanas (n = 8), os animais foram sacrificados. As lâminas (coradas com Picro-Sirius) foram analisadas por microscopia óptica normal e software específico. Resultados: Os grupos com o osso autógeno se mostraram muito superiores aos demais nos dois tempos analisados, tendo média de neoformação óssea ± DP de 90,6 ± 10,8% em seis semanas, e 98 ± 9,2% em 12 semanas (p > 0,0001 em ambos os tempos analisados). Em seis semanas, os resultados para os demais grupos foram os seguintes: Genphos ® , 46 ± 7,1%; HA, 43,1 ± 8,4%; e GenMix ® , 57,3 ± 4,5%. Em 12 semanas: Genphos ® , 47,8 ± 11,1%; HA, 39,9 ± 5,4%; GenMix ® , 59,7 ± 4,8%, significativa (p = 0,007). Conclusões: Em ambos os tempos analisados, os três materiais de substituição óssea testados se mostraram inferiores ao osso autógeno quanto à percentagem de neoformação óssea. Picro-Sirius) were assessed by optical microscopy and specific software. Results: The groups with autologous bone were shown to be significantly superior to the others at both assessed times, showing a mean bone formation rate ± SD of 90.6 ± 10.8% in six weeks, and 98 ± 9.2% in 12 weeks (p > 0.0001 for both assessed times). In six weeks, the results for the other groups were the following: Genphos ® , 46 ± 7.1%; HA, 43.1 ± 8.4%; and GenMix ® , 57.3 ± 4.5%. In 12 weeks: Genphos ® , 47.8 ± 11.1%; HA, 39.9 ± 5.4%; GenMix ® , 59.7 ± 4.8%, significant (p = 0.007 Descritores Each of the four defects produced was filled by autologous bone or by one of three tested materials -hydroxyapatite (HA), Genphos ® (HA+ ß-TCP) and GenMix ® (a combined bovine bone graft). In the end of the 6-week (n = 6) and 12-week (n = 8) periods, the animals were sacrificed. The sections (stained with

show abstract

A triphasic ceramic-coated porous hydroxyapatite for tissue engineering application

Cited by 71 publications

References 24 publications

Comparison of computed tomography and microradiography for graft evaluation after reconstruction of critical size bone defects using β-tricalcium phosphate

Comparison of computed tomography and microradiography for graft evaluation after reconstruction of critical size bone defects using β-tricalcium phosphate

Application of β-1,3-glucan in production of ceramics-based elastic composite for bone repair

Estudo comparativo da neoformação óssea utilizando-se o enxerto autógeno e três substitutos: defeitos ósseos em ratos

Contact Info

Product

Resources

About